The clinical information you need, at your fingertips.

Newly approved use broadens access to a once-daily oral JAK inhibitor for younger patients with challenging disease. . .

Phase 3 TRIUMPH-2 results suggest the triple-agonist delivers substantial weight loss and glycemic improvements over 80 weeks. . .

Sugar-rich foods eaten during broad-spectrum courses predicted a substantial diet-linked decline in gut bacterial diversity. . .

A new ACC nutrition statement challenges federal dietary guidance, naming higher protein targets and full-fat animal foods as not aligned with the evidence. . .

One analysis favors raising the semaglutide dose over switching, while the other favors tirzepatide over high-dose semaglutide. But neither is a head-to-head test. . .

Visit-to-visit BP variability may provide prognostic information beyond average BP levels. . .